Literature DB >> 2000253

Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys.

P P Vella1, R W Ellis.   

Abstract

Two Haemophilus influenzae type b (Hib) polysaccharide-protein conjugate vaccines were evaluated for immunogenicity in eliciting anti-polyribosyl ribitol phosphate (PRP) antibodies in infant rhesus monkeys. Animals received intramuscular injections of either Hib polysaccharide (PRP)-meningococcal outer membrane protein complex or Hib oligosaccharide-CRM197 (HbOC) conjugate vaccines on d 0, 28, and 56. Because HbOC contains the CRM197 mutant diphtheria toxin from Corynebacterium diphtheriae as its protein carrier, the effect of simultaneous injection of diphtheria toxoid on the immunogenicity of HbOC also was evaluated by dividing monkeys vaccinated with HbOC into three groups: HbOC/saline, HbOC/diphtheria and tetanus toxoids, and HbOC/tetanus toxoid (coadministration of HbOC and other vaccine or placebo injected into the flank muscle of different legs). Infant monkeys vaccinated with the PRP-outer membrane protein complex conjugate responded with anti-PRP antibody after the first dose and showed booster responses after the second and third injections. In contrast, infant monkeys vaccinated with HbOC did not respond after three doses of HbOC/saline or HbOC/tetanus toxoid. However, two of three monkeys given concurrent injections of HbOC and diphtheria and tetanus toxoids did respond. The nonresponder monkey to three doses of HbOC and diphtheria and tetanus toxoids did respond to a subsequent injection with PRP-outer membrane protein complex. Thus, concomitant administration of diphtheria toxoid, a common vaccine for human infants, is necessary to elicit an anti-PRP antibody response to HbOC.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2000253     DOI: 10.1203/00006450-199101000-00003

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  12 in total

1.  Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group.

Authors:  D M Granoff; P G Shackelford; S J Holmes; A H Lucas
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 2.  Conjugate vaccines: practice and theory.

Authors:  R S Becker
Journal:  Springer Semin Immunopathol       Date:  1993

Review 3.  Content and dynamics of the human antibody variable region repertoire to the Haemophilus influenzae type b polysaccharide.

Authors:  D C Reason; A H Lucas
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.

Authors:  C C Peeters; D Evenberg; P Hoogerhout; H Käyhty; L Saarinen; C A van Boeckel; G A van der Marel; J H van Boom; J T Poolman
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

5.  Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

Authors:  K K van Rompay; P J Dailey; R P Tarara; D R Canfield; N L Aguirre; J M Cherrington; P D Lamy; N Bischofberger; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes.

Authors:  M A Liu; A Friedman; A I Oliff; J Tai; D Martinez; R R Deck; J T Shieh; T D Jenkins; J J Donnelly; L A Hawe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

7.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

8.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.

Authors:  C C Peeters; A M Tenbergen-Meekes; J T Poolman; M Beurret; B J Zegers; G T Rijkers
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; A Gyhrs; K Kristensen; C Heilmann
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Authors:  K K Van Rompay; M L Marthas; R A Ramos; C P Mandell; E K McGowan; S M Joye; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.